Nuvectis Pharma, Inc. (NVCT) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 2 Buy.
The consensus price target is $10.00, representing an upside of 14.5% from the current price $8.73.
Analysts estimate Earnings Per Share (EPS) of $-1.01 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.11 vs est $-1.01 (missed -10.3%). 2025: actual $-1.32 vs est $-1.32 (beat +0.3%). Analyst accuracy: 95%.
NVCT Stock — 12-Month Price Forecast
$10.00
▲ +14.55% Upside
Average Price Target
Based on 2 Wall Street analysts offering 12-month price targets for Nuvectis Pharma, Inc., the price target is $10.00.
The average price target represents a +14.55% change from the last price of $8.73.
NVCT Analyst Ratings
Buy
Based on 2 analysts giving stock ratings to Nuvectis Pharma, Inc. in the past 3 months
EPS Estimates — NVCT
95%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.11
vs Est –$1.01
▼ 9.3% off
2025
Actual –$1.32
vs Est –$1.32
▲ 0.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — NVCT
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
